Johannes Jacob Pieter Kastelein
Director, Chief Scientific Officer · 2 filings · Latest: Mar 5, 2026
NewAmsterdam Pharma Co N.V.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
NAMS | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Mar 9, 2026 | Sale | $30.29 | 101,409 | $3.1M | 69,302 | |
NAMS | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Mar 9, 2026 | Option Exercise | — | 101,409 | — | 170,711 | |
NAMS | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Mar 6, 2026 | Sale | $30.32 | 94,124 | $2.9M | 69,302 | |
NAMS | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Mar 6, 2026 | Option Exercise | — | 94,124 | — | 163,426 | |
NAMS | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Mar 5, 2026 | Sale | $30.30 | 104,467 | $3.2M | 69,302 | |
NAMS | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Mar 5, 2026 | Option Exercise | — | 104,467 | — | 173,769 | |
NAMS | Kastelein Johannes Jacob Pieter | — | Mar 2, 2026 | Proposed Sale | $31.18 | 300,000 | $9.4M | — | |
NAMS | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Feb 20, 2026 | Sale | $35.31 | 45,481 | $1.6M | 53,500 | |
NAMS | Kastelein Johannes Jacob Pieter | — | Feb 20, 2026 | Proposed Sale | $34.63 | 45,481 | $1.6M | — | |
NAMS | Johannes Kastelein | — | Jan 5, 2026 | Proposed Sale | $33.25 | 6,000 | $199.5K | — | |
NAMS | Kastelein Johannes Jacob Pieter | — | Aug 21, 2025 | Proposed Sale | $25.00 | 100,000 | $2.5M | — |